MSLN and malignant pleural mesothelioma: To this extent, an antitumor immune response suggesting epitope spreading was observed following mesothelin-specific mRNA CAR T cells treatment in a case study on two patients with malignant pleural mesotheliomas and metastatic pancreatic cancer, respectively [101].